News
Video
Author(s):
Delve into the exciting developments in endometrial cancer treatment, including HER2 antibody drug conjugates, checkpoint inhibitors, and the promising impact of these therapies in the quest to reduce chemotherapy use.
Lunresertib Plus Camonsertib Produces Durable Responses in Advanced Endometrial, Ovarian Cancer
Monk and Tarantino Describe the Investigation of B7-H4 Vedotin–Directed ADCs in Gynecologic and Breast Cancers
New ADCs Join NCCN Guidelines for Gynecologic Cancers Representing Step Forward
Simeone and Fakih Detail Research Objectives With A2B530 in CEA-Expressing Solid Tumors
FDA Grants Fast Track Designation to CRB-701 in Relapsed/Refractory Cervical Cancer
Cadonilimab Plus Chemotherapy Provides Frontline Survival Benefit in Metastatic Cervical Cancer
Perioperative Pembrolizumab Regimen Upholds Survival Benefit in Resectable NSCLC
Zongertinib Elicits Durable Responses in Pretreated Advanced HER2-Mutant NSCLC
Lenvatinib Shows Efficacy in Advanced HCC Post-Progression on Atezolizumab/Bevacizumab
Sacituzumab Govitecan Does Not Significantly Improve OS in Pretreated Urothelial Carcinoma